Navigation Links
AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies
Date:9/24/2013

ammation, AbbVie and Galapagos signed a worldwide license agreement whereby AbbVie will be responsible for further development and commercialization of GLPG0634 after Phase 2B.  GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, currently in Phase 2B studies in RA and about to enter Phase 2 studies in Crohn's disease. 

The Galapagos Group, including fee-for-service companies BioFocus, Argenta and Fidelta, has 800 employees and operates facilities in five countries, with global headquarters in Mechelen, Belgium.  Further information at: www.glpg.com

Galapagos forward-looking statements
This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any ch
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. AbbVie Named to S&P 500 Dividend Aristocrat Index
2. AbbVie Issues Inaugural Full-Year Outlook for 2013
3. AbbVie to Present at Barclays Global Health Care Conference
4. Receptos Licenses Anti-Interleukin-13 Antibody from AbbVie for Phase 2 Development in Orphan Disease
5. AbbVie to Host First-Quarter Earnings Conference Call
6. AbbVie Reports First-Quarter 2013 Financial Results
7. AbbVie CF Scholarship Application Now Available for Exceptional Undergraduate and Graduate Students with Cystic Fibrosis
8. AbbVies Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
9. AbbVie to Present at Bank of America Merrill Lynch 2013 Health Care Conference
10. AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
11. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission ... ResMed (RMD) against BMC Medical. In a notice issued on ... found that ResMed,s patent on its humidifier was invalid. ... a "monumental win". "We are very excited with the ITC,s ... position that we have taken since the very beginning on ...
(Date:12/24/2014)... 24, 2014  Diplomat Pharmacy, Inc. (NYSE: ... proud to announce Jennifer Hagerman , Pharm.D., AE-C, ... take office as the president of the Michigan Pharmacists ... will take place Feb. 28, 2015, at the MPA ... the Renaissance Center in Detroit, Michigan ...
(Date:12/24/2014)... NEW YORK and LONDON ... in global orthopedic industry are expected to grow at ... consumption in terms of value and volume. Hip, knee ... the developed world while in emerging economies they have ... failure rates are challenging the use of composites. Non-metallic ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
... U.S. Agency for International Development (USAID) continues to provide ... the midst of an expanding humanitarian crisis. An ailing ... the people of Zimbabwe in danger of other health ... supporting emergency Indoor Residual Spraying (IRS) to shore up ...
... high Dk hybrid contact lens manufacturer, announced today the ... fund the development and clinical trials for next-generation hybrid ... efforts globally. De Novo Ventures of Palo Alto, CA, ... round. Bio-Star Private Equity Fund joined Series A and ...
Cached Medicine Technology:USAID Provides Malaria Assistance to Zimbabwe 2SynergEyes, Inc. Raises $13.3 Million in 'Series C' Financing 2
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... 29 Four leaders,from the worlds of medicine, research, ... national Board of Trustees of the March of,Dimes Foundation, ... who serve as volunteers, represent the public,in governing the ... The new trustees are:, Miriam Arond, Director of ...
... ROCK, Ark., July 29 Heifer International and,Elanco ... partnership,agreement. Heifer International is a world hunger organization. ... Indiana, that has,offices in 30 countries around the ... animal health and productivity., The partnership will ...
... organized population-based breast cancer screening program in Norway and ... self-referrals in Vermont are equally sensitive for detecting cancer, ... the Journal of the National Cancer Institute . ... in Norway. , Breast cancer screening in the United ...
... Ultra-miniature bialy-shaped particles called nanobialys because they ... popular in New York City could soon ... tumors or atherosclerotic plaques. , The nanobialys ... diagnostic and disease-fighting nanoparticles developed by researchers in ...
... $0.56 Net Income Per Share, SAN JOSE, Calif., ... ), a leading provider of medical devices,for the minimally ... for the second quarter ended June 30, 2008., ... 85% to $31.9,million compared with $17.2 million for the ...
... Q2 net revenues of $79.9 million increase 6.9 percent sequentially ... $0.06 per diluted share - Case ... cost-saving measures including a workforce reduction, SANTA CLARA, Calif., July ... results for the,second quarter of fiscal 2008, ended June 30, 2008., ...
Cached Medicine News:Health News:Four Named to March of Dimes Board of Trustees 2Health News:Four Named to March of Dimes Board of Trustees 3Health News:Four Named to March of Dimes Board of Trustees 4Health News:Four Named to March of Dimes Board of Trustees 5Health News:Four Named to March of Dimes Board of Trustees 6Health News:Four Named to March of Dimes Board of Trustees 7Health News:Heifer and Elanco Announce Charitable Partnership 2Health News:2 different breast cancer screening strategies are equally effective 2Health News:New disease-fighting nanoparticles look like miniature pastries 2Health News:New disease-fighting nanoparticles look like miniature pastries 3Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 2Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 3Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 4Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 5Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 6Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 7Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 8Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 2Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 3Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 4Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 5Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 6Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 7Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 8Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 9Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 10Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 11Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 12Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 13
... it is not the Flu? Streptococcus pneumoniae ... "flu-like" infections. The easy-to-use, rapid, urine-based test ... the new 4 hour guidelines. Rapid identification ... patient outcomes and lower overall health care ...
... newest technology available in acrylic lens design. ... material and design properties to achieve truly ... Unique foldable hydrophobic acrylic material , ... , High index of refraction ...
12 mm single use, reloadable laparoscopic linear stapler with titanium staples....
Single Use Loading Units (SULU's) Knifeless for use with MULTIFIRE ENDO GIA™ 30 12 mm (Single Use Staplers with Titanium Staples)....
Medicine Products: